CCEL — Cryo-Cell International Share Price
0.000.00%
Last trade - 00:00- $68.48m
- $76.06m
- $31.34m
- 76
- 23
- 86
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 126.61 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -41.22% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.1% | ||
| Return on Equity | n/a | ||
| Operating Margin | -41.97% | ||
Financial Summary
| Year End 30th Nov | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 31.82 | 31.15 | 28.88 | 30.34 | 31.34 | 31.78 | 35.21 | 1.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +54.28 | +42.16 | -44.63 | -20.78 | -40.27 | -82.47 | +300 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
Directors
- David Portnoy CHM (58)
- Mark Portnoy CCE (57)
- Jill Taymans CFO (51)
- Oleg Mikulinsky CIO (48)
- Daniel Mizrahi DRC
- Harold Berger IND (57)
- Last Annual
- November 30th, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- September 11th, 1989
- Public Since
- April 4th, 1994
- No. of Shareholders
- 1,644
- No. of Employees
- 82
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 8,104,477
- Address
- 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR, 34677
- Web
- https://www.cryo-cell.com/
- Phone
- +1 8137492104
- Contact
- Irene Smith
- Auditors
- Wipfli LLP
Upcoming Events for CCEL
Cryo-Cell International Inc Annual Shareholders Meeting
Q3 2024 Cryo-Cell International Inc Earnings Release
Similar to CCEL
National Healthcare
NYSE MKT
Zomedica
NYSE MKT
FAQ
What is the Cryo-Cell International share price?
As of Today at 07:06 UTC, shares in Cryo-Cell International are trading at $8.45. This share price information is delayed by 15 minutes.
How has the Cryo-Cell International share price performed this year?
Shares in Cryo-Cell International last closed at $8.45 and the price had moved by +48.51% over the past 365 days. In terms of relative price strength the Cryo-Cell International share price has outperformed the S&P500 Index by +21.41% over the past year.
What are the analyst and broker recommendations for Cryo-Cell International?
The overall consensus recommendation for Cryo-Cell International is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cryo-Cell International dividend yield?
Cryo-Cell International does not currently pay a dividend.
Does Cryo-Cell International pay a dividend?
Cryo-Cell International does not currently pay a dividend.
When does Cryo-Cell International next pay dividends?
Cryo-Cell International does not currently pay a dividend.
How do I buy Cryo-Cell International shares?
To buy shares in Cryo-Cell International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cryo-Cell International?
As of the previous close price of $8.45, shares in Cryo-Cell International had a market capitalisation of $68.48m.
Where are Cryo-Cell International shares listed?
Here are the trading details for Cryo-Cell International:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: CCEL
What kind of share is Cryo-Cell International?
Based on an overall assessment of its quality, value and momentum Cryo-Cell International is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cryo-Cell International share price forecast for 2024?
The analyst consensus target price for shares in Cryo-Cell International is $9.00. That is 6.51% above the last closing price of $8.45.
Analysts covering Cryo-Cell International currently have a consensus Earnings Per Share (EPS) forecast of $0.03 for the next financial year.
What is the trend in the Cryo-Cell International share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cryo-Cell International. Over the past six months, its share price has outperformed the S&P500 Index by +44.13%.
As of the last closing price of $8.45, shares in Cryo-Cell International were trading +47.58% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cryo-Cell International PE Ratio?
The Cryo-Cell International PE ratio based on its reported earnings over the past 12 months is 126.61. The shares last closed at $8.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cryo-Cell International?
Cryo-Cell International's management team is headed by:
- David Portnoy - CHM
- Mark Portnoy - CCE
- Jill Taymans - CFO
- Oleg Mikulinsky - CIO
- Daniel Mizrahi - DRC
- Harold Berger - IND